Although sarcopenia is a common complication of cirrhosis, its diagnosis remains nonconsensual: computed tomography (CT) scan determinations vary and no cutoff values have been established in cirrhotic populations undergoing liver transplantation (LT). Our aim was to compare the accuracy of the most widely used measurement techniques and to establish useful cutoffs in the setting of LT. From the 440 patients transplanted between January 2008 and May 2011 in our tertiary center, we selected 256 patients with cirrhosis for whom a recent CT scan was available during the 4 months prior to LT. We measured different muscle indexes: psoas muscle area (PMA), PMA normalized by height or body surface area (BSA), and the third lumbar vertebra skeletal muscle index (L3SMI). Receiver operating characteristic curves were evaluated and prognostic factors for post-LT 1-year survival were then analyzed. PMA offered better accuracy (area under the curve [AUC] 5 0.753) than L3SMI (AUC 5 0.707) and PMA/BSA (AUC 5 0.732), and the same accuracy as PMA/ squared height. So, for its accuracy and simplicity of use, the PMA index was used for the remainder of the analysis and to define sarcopenia. In men, the better cutoff value for PMA was 1561 mm 2 (Se 5 94%, Sp 5 57%), whereas in women, it was 1464 mm 2 (Se 5 52%, Sp 5 91%). A PMA lower than these values defined sarcopenia in patients with cirrhosis awaiting LT. One-and 5-year overall survival rates were significantly poorer in the sarcopenic group (n 5 57) than in the nonsarcopenic group (n 5 199), at 59% versus 94% and 54% versus 80%, respectively (P < 0.001). In conclusion, pre-LT PMA is a simple tool to assess sarcopenia. We established sex-specific cutoff values (1561 mm 2 in men, 1464 mm 2 in women) in a cirrhotic population and showed that 1-year survival was significantly poorer in sarcopenic patients.
Cirrhosis is the end stage of many liver diseases, and its only curative treatment is liver transplantation (LT). According to the principle of utility, graft allocation is now based on the Model for End-Stage Liver Disease (MELD) score (1) that has been used to predict mortality on the waiting list. (2) However, this score is a poor predictor of mortality following transplantation, (3) and numerous factors not reflected by the MELD score may increase postoperative complications (i.e. pre-transplant weight loss, hypoalbuminemia, ascitis, marginal graft). Not registering a patient on the waiting list because of his poor general condition is a very difficult choice, and patient frailty is currently judged from subjective clinical impressions. (4) Denutrition is a frequent complication of cirrhosis, often neglected, (5, 6) as the management of patients with cirrhosis mainly focuses on other complications. Unfortunately, it is very difficult to improve the nutritional status of cirrhotic patients, (7) and denutrition cannot be reversed rapidly after LT. Indeed, denutrition may even worsen during the early weeks following LT (8) (9) (10) before a slow and gradual gain. (11) Abbreviations: AUC, area under the curve; BMI, body mass index; BSA, body surface area; CI, confidence interval; CIT, cold ischemia time; CMV, cytomegalovirus; CT, computed tomography; DUS, Doppler ultrasound; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HR, hazard ratio; ICU, intensive care unit; INR, international normalized ratio; L3SMI, third lumbar vertebra skeletal muscle index; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PMA, psoas muscle area; PNF, primary nonfunction; POD, postoperative day; RBC, red blood cell; ROC, receiver operating characteristic; SD, standard deviation; Se, sensibility; Sp, specificity; TIPS, transjugular intrahepatic portosystemic shunt; WIT, warm ischemia time.
Denutrition results in a progressive loss of muscle mass, defined as sarcopenia. Sarcopenia has been used as a marker of poor general status when predicting outcomes in various populations undergoing general surgery (12) or renal transplantation. (13) Sarcopenia is a better objective measure of denutrition in patients with cirrhosis than serum (pre-) albumin, weight, and body mass index (BMI), which may be modified by hepatopathy or ascites. Low muscle mass has been shown to be a risk factor for death among patients on the LT waiting list, and especially those with low MELD score <15. (14) In the setting of whole graft LT, this prognostic factor remains controversial because some authors have not found any correlation between sarcopenia and posttransplant mortality. (15, 16) However, a recent meta-analysis confirmed the negative impact of sarcopenia on post-LT outcomes. (17) In the literature, computed tomography (CT) measurements of a loss of skeletal muscles in patients with cirrhosis include a wide variety of nonconsensual tools that have not been evaluated specifically in this population:
1. Psoas cross-sectional area without any normalization.
2. Psoas "thickness" normalized by height. (19) 3. Total muscle and fat area at the level of the third lumbar vertebra. (20) 4. Third lumbar vertebra skeletal muscle index (L3SMI) normalized by the squared height. (14, 19, 21, 22) Because of the heterogeneity of definitions, the European Working Group on Sarcopenia recently pointed out that "more research is urgently needed in order to obtain good reference values." (23) In fact, there is currently no specific cutoff value for sarcopenia in patients with cirrhosis, as the L3SMI cutoff value has been determined from obese cancer patients, (24) and the psoas area does not have any published cutoff value calculated from patients with cirrhosis. For example, the cutoff values of psoas area proposed by Tsien et al., (10) Masuda et al., (25) and Jeon et al. (16) were based on healthy controls whereas Hamaguchi et al. (26) presented psoas area cutoff in living donor LT from patients with cirrhosis and patients without cirrhosis. It should also be noted that most of the studies evaluating sarcopenia were published in living donor LT, not in whole graft LT.
The aims of this study were therefore to compare the 4 most useful measures (published) and to determine the simplest method to define sarcopenia on preoperative CT scans of recipients, and to identify the best cutoff value that could predict 1-year postoperative mortality. Longterm survival was also assessed.
Patients and Methods

STUDY POPULATION AND DESIGN
Patients were selected retrospectively from a prospective database of adult patients transplanted in our tertiary center between January 2008 and May 2011. From the 440 transplanted patients, we selected the 256 patients who had histologically proven cirrhosis and for whom a recent CT scan was available (during the 4 months prior to LT). Follow-up was halted on April 1, 2016.
MUSCLE AREA MEASUREMENT ON CT SCANS
Careful consideration was given to the renal function before performing a contrast-enhanced CT scan because iodinated contrast injection may worsen a preexisting and undiagnosed renal failure (normal creatininemia because of low muscle mass). Injection was contraindicated in case of end-stage renal failure (unless dialysis).
The CT scans were analyzed retrospectively using Myrian XP-Liver 1.14.1 Software (Intrasense, Montpellier, France), and a cross section was selected close to the intervertebral disk between the level of the third and fourth lumbar vertebra. The surface areas of both psoas muscles and of other skeletal muscles were calculated in a semiautomatic fashion using the 2-dimensional module (Fig. 1 ). In the case of a nonenhanced CT scan, psoas area measures were manually defined. Four quantifications of skeletal muscle mass were performed by the same operator (P.O.B.): psoas muscle area (PMA, sum of the areas of the 2 psoas at the level of the third or fourth lumbar vertebra), PMA normalized either by body surface area (BSA) or by squared height, and L3SMI (sum of the area of all skeletal muscles at the level of the third vertebra).
SURGICAL PROCEDURES
Deceased donor LT, living donor LT, split-liver LT, and domino LT were performed using previously described techniques. (27) (28) (29) (30) At the end of LT, an intraoperative Doppler ultrasound (DUS) was performed systematically.
SHORT-TERM POSTOPERATIVE MANAGEMENT
Until postoperative day (POD) 7, daily DUS was ensured. All patients received a routine triple immunosuppressive regimen. Following their discharge, longterm aspirin therapy was prescribed to reduce the risk of arterial thrombosis. A CT scan was performed between POD 7 and 10 unless contraindicated.
LONGTERM POSTOPERATIVE MANAGEMENT
Following their discharge, patients visited our outpatient clinic every 2 weeks for the first 2 months, and 
DEFINITIONS
Denutrition was defined as BMI < 18.5 kg/m 2 and/or albuminemia <30 g/L, (31, 32) as in the general population because no other definition is available for patients with cirrhosis. Perioperative morbidity or mortality was defined as an event occurring during initial hospitalization or before POD 90. Primary nonfunction (PNF) was considered as graft failure occurring within hours after revascularization with no discernible cause and leading to retransplantation or death. Acute cellular rejection suspicion was confirmed by liver histology, based on the Banff histological criteria.
STATISTICAL ANALYSIS
Patient follow-up started at LT, and the patients were followed until death or the end of the study. Our primary endpoint was 1-year mortality. Continuous variables were presented as mean 6 standard deviation (SD) or median (range). Categorical variables were presented as percentages. The prognostic value of different measures of skeletal muscle was evaluated on a receiver operating characteristic (ROC) curve analysis using 1-year survival as the endpoint. Cutoff values were chosen using the Youden index. Univariate and multivariate risk factor analysis was performed using logistic regression for 1-year survival and Cox proportional hazard model analysis for survival. Multivariate analysis included all values with P < 0.1. Comparisons between groups were made according to Student t test for continuous variables and Fisher's exact test for categorical variables. Correlations were calculated using Pearson's and Spearman's rho analysis. Risk factor analysis was performed using bivariate logistic regression for 1-year mortality. Cumulative survival curves were drawn using the Kaplan-Meier method and compared by means of the log-rank test. The data were analyzed using SPSS 20 (IBM, Armonk, NY).
Results
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS (WHOLE COHORT)
No patient was lost to follow-up. The mean age of recipients at LT was 53 6 11 years, with a mean BMI of 25.3 6 4.4 kg/m 2 (14.7-39.7 kg/m 2 ; Table 1 ). Only 6 (2.3%) patients presented with an anthropometric definition of denutrition (BMI < 18.5 kg/m 2 ). The mean serum albumin level was 31 6 6 g/L (14-54 g/L), with 41% of recipients suffering from biological denutrition. No cases of acute renal failure occurred after performing a contrast-enhanced CT scan. 
INTRAOPERATIVE FEATURES AND POSTOPERATIVE OUTCOMES (WHOLE COHORT)
PNF occurred in 5 patients, leading to retransplantation (n 5 4) or death (n 5 1; NOTE: Values represent mean 6 SD for quantitative variables and n (%) for qualitative variables. *Postoperative mortality 5 death in hospital or before POD 90.
FIG. 2.
ROC curve analysis of different types of measurement of skeletal muscle on a CT scan: L3SMI, PMA, ie, the sum of the 2 PMAs at the level of the third or fourth vertebra, crude ("psoas surface") or normalized by BSA ("psoas/BSA") and by squared height ("psoas/height 2 ").
and 17 (6.6%; 10 stenosis and 7 thrombosis) patients, respectively.
SKELETAL MUSCLE MEASURES ON CT SCAN CROSS SECTIONS
The ROC curve analysis for 1-year mortality showed that the PMA and the PMA normalized by squared height had the best statistical significance (P < 0.001) with same area under the curve (AUC) value of 0.753 (Fig. 2 ). L3SMI and PMA/BSA had respective AUC values of 0.707 and 0.732. So, for its accuracy and simplicity of use (not requiring BSA or height data), the PMA index was used for the remainder of the analysis. Men had larger mean PMA values than women (2211 6 666 mm 2 versus 1410 6 357 mm 2 ; P < 0.001). For this reason, we stratified the ROC curve analysis according to sex and calculated the best couple of sensibility (Se) and specificity (Sp; Fig. 3 ). In men, the AUC was of 0.764 and the cutoff value for PMA was 1561 mm 2 (Se 5 94%; Sp 5 57%), whereas in women AUC was of 0.70 and the cutoff was 1464 mm 2 (Se 5 52%; Sp 5 91%). A PMA lower than these values defined sarcopenia. Among the 256 patients, 57 (22%) belonged to the "sarcopenic group."
SURVIVAL ANALYSIS
Three-month, 1-year, and 5-year overall survival rates were significantly poorer in the sarcopenic group than in the nonsarcopenic group at 82% versus 98%, 59.2% versus 94.5%, and 53.6% versus 79.8%, respectively (P < 0.001; Fig. 4) . The most excessive mortality in the sarcopenic group occurred during the first year, after which the curves remained grossly parallel.
COMPARISON OF PERIOPERATIVE DATA BETWEEN SARCOPENIC AND NONSARCOPENIC PATIENTS
A preoperative analysis of both groups showed that sarcopenic patients were more often women (58% versus 14%; P < 0.001), presenting a lower BMI (23.8 versus 25.8 kg/m 2 ; P 5 0.003), and a higher frequency of ascites (72% versus 51%; P 5 0.006) and thrombocytopenia (74 versus 90 g/L; P 5 0.03; Table 3 ). Sarcopenic recipients presented a higher MELD score (22 versus 18; P 5 0.01). There was no difference with respect to the etiology of cirrhosis or the presence of hepatocellular carcinoma (HCC).
Analysis of the intraoperative data did not reveal any difference between the 2 groups.
Sarcopenic patients presented with a longer intensive care unit (ICU) stay (22 versus 9 days; P < 0.001), and higher severe morbidity (63% versus 37%; P < 0.001) and postoperative mortality (Clavien V, 21% versus 1.5%; P < 0.001). They more frequently experienced severe infections, in particular lung 
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infections requiring mechanical ventilation, seizures, and kidney failure, than nonsarcopenic patients. There was a trend toward less acute rejection in sarcopenic patients (P 5 0.09). The PMA was weakly correlated to recipient weight (P < 0.001; r 5 0.307). There was no correlation between PMA and preoperative albuminemia levels (r 5 0.03), MELD score (r 5 20.2), height (r 5 0.148), or BMI (r 5 0.25).
The principal cause of death among sarcopenic patients was bacterial or fungal infection (especially lung infections), as well as pulmonary and renal failure.
PREOPERATIVE AND INTRAOPERATIVE PREDICTIVE FACTORS FOR 1-YEAR MORTALITY
Under univariate analysis of preoperative characteristics with respect to 1-year mortality, significant risk factors were sarcopenia (P < 0.0001), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infections (P 5 0.003 and P 5 0.01, respectively; Tables 4 and 5) . Preoperative ascites and albumin values did not reach a level of significance. Among intraoperative data, a cytomegalovirus (CMV)-positive graft (P 5 0.05), the transfusion of more than 6 red blood cell (RBC) units (P 5 0.04), over 12 hours of cold ischemia time (CIT; P 5 0.03), and over 90 minutes of warm ischemia time (WIT; P 5 0.01) were predictive of 1-year mortality. No donorrelated prognostic factors impacted 1-year survival.
Under multivariate, sarcopenia was the most important predictive factor (P < 0.001), with a hazard ratio (HR) of 17.62 (95% confidence interval [CI], 6.04-51.37). HCV infection (P 5 0.02), CMVpositive donors (P 5 0.02), over 12 hours of CIT (P 5 0.01), and over 90 minutes of WIT (P 5 0.01) were also associated with a higher risk of mortality.
In the sarcopenic group, HCV infection was the only significant risk factor for 1-year mortality (P 5 0.052), but HIV-infected patients also presented a trend toward a worse prognosis (P 5 0.09). However, multivariate analysis did not demonstrate any significant risk factor (HCV positive, P 5 0.18; HIV positive, P 5 0.26). Note that HCV-positive/HIV-positive coinfected sarcopenic recipients (n 5 5) presented a poor 1-year survival (20%), with only 1 longterm survivor (57 months).
Discussion
STATEMENT OF PRINCIPAL FINDINGS
By focusing on the 4 indexes most frequently used to define sarcopenia, in order to standardize this definition and its management in LT setting, we demonstrated that a PMA measurement, although suboptimal, offered the best accuracy to predict outcome, and we established that sex-specific cutoff values of 1561 mm 2 in men and 1464 mm 2 in women achieved greater accuracy in predicting 1-year survival after LT. We also confirmed the poorer outcomes of sarcopenic patients with cirrhosis with significantly higher postoperative morbidity and lower survival.
STRENGTHS AND WEAKNESSES OF THE STUDY
The main strength of this study was that it established the first cutoff values specifically calibrated in a pre-LT cirrhotic population. This series also offered lengthy follow-up (58 months) of patients in a high-volume center. However, 1-year mortality was chosen as the primary endpoint because peak mortality in sarcopenic patients occurred during the first postoperative year. The main advantage of the PMA measure is its simplicity of use, even by a nonradiologist because it only requires volumetric software and a recent CT scan, eventually performed without injection in the case of renal failure. This simple index and its newly defined cutoff values could be used to homogenize practices. Of course, the low AUC value (<0.8) may be an obstacle to consider the PMA as a gold standard measure even if it represents the best value reached in such a setting. To date, definition of sarcopenia in cirrhotic recipients remains imprecise, based on current measures for a daily practice and most authors do not follow the European recommendations. (23) However, our aim was not to define a more accurate new measure but to compare the known tools and determine specific cutoffs in patients with cirrhosis.
The limitations of the study were as follows:
1. Its retrospective design. 2. The lack of patients treated with new anti-HCV therapies. 3. The inter-rater reliability was not assessed. 4. Only 256/440 patients were included, mainly because other patients did not have a recent CT scan available, or no imaging with slices covering 
INTERPRETATION WITH REFERENCE TO OTHER STUDIES
The MELD score is an imperfect reflection of the general status of recipients, as has been shown by various attempts to improve it. (3, 33) In our univariate analysis of predictors for 1-year survival in a group of sarcopenic patients, the MELD score did not reach the significance threshold. This may be partly explained because the creatininemia (included in the MELD formula) is not a valuable measure to quantify the renal dysfunction in that situation of low muscle mass.
Although accepted as a reliable prognostic factor for survival, some authors have not shown any significant impact of sarcopenia. (15, 16) Our findings clearly confirmed the poorer survival of sarcopenic recipients, particularly their excessive mortality during the early months after LT.
Assessing nutritional status and protein balance is a difficult issue in patients with cirrhosis. Laboratory variables lack accuracy because of their hepatic synthesis, the administration of medications, and inflammation. Only 45% of our sarcopenic group presented with hypoalbuminemia, and there was no correlation between PMA and albuminemia. Estimating muscle mass for the diagnosis of sarcopenia has recently been developed as a valuable tool in order to assess the nutritional status of patients with many chronic conditions. (13, 24, (34) (35) (36) In LT candidates, it remains difficult to quantify sarcopenia because anthropometric measures lack precision and reproducibility. Furthermore, most anthropometric parameters are overestimated because of edema and ascites. In our cohort, 98% of sarcopenic patients presented with normal BMI values, and 3 nonsarcopenic patients were suffering from denutrition according to their BMI. This confirms the poor correlation observed between PMA and BMI (r 5 0.251). (20) Muscle size measurements on CT scan are considered to be the gold standard in research settings. (23) For patients waiting for LT, CT scans form part of routine checks before listing, so in this particular setting, there are no additional costs or supplementary X-ray exposure. To our knowledge, no comparison has previously been reported in the literature between different measurement systems for LT candidates, and different teams tend to promote their own indexes. Furthermore, no published cutoff value has been determined specifically in patients with cirrhosis undergoing LT (most values have been calibrated in control groups-mainly healthy populations), and none are suitable for patients with end-stage liver disease. (11, 37) To address this issue, some authors have defined sarcopenia using muscle area stratification by tertile, quartile, or percentile from control groups, (10, 16, 18, 25, (38) (39) (40) (41) (42) but without justifying their cutoff value or assessing if these values accurately predicted the studied endpoint.
Almost all authors to date have used an axial section at the level of the third or fourth lumbar vertebra. Measuring PMA rather than all skeletal muscle area is simpler, faster, and probably more informative because ascites and associated abdominal wall edema may render measurements of peripheral abdominal skeletal muscle less accurate. The L3SMI was determined in patients without cirrhosis and was then extrapolated to patients with cirrhosis without any adjustment. (14, 21) Our study has demonstrated that the predictive value of PMA for post-LT 1-year survival was better than that of L3SMI. In our experience, normalizing this value by the BSA or squared height did not improve it further. Durand et al. (19) measured psoas muscle thickness normalized to stature by dividing it by height, but their choice seems questionable: first, the level of the axial section analyzed was at the umbilicus, whose position may vary depending on the type of obesity and amount of ascites. Second, they chose the largest diameter of the right psoas visually, and defined "transverse psoas thickness" as the diameter perpendicular to this diameter. The axial shape of the psoas may differ markedly in each patient, and the psoas is larger on the dominant side. Furthermore, the authors used muscle atrophy as a prognostic value for mortality on the waiting list, but not for post-LT mortality. DiMartini et al. (22) used a specific software to analyze body composition. This time-consuming technique is difficult to use in daily practice. Unfortunately, they used a cutoff value based on findings in the literature on cancer, not in a context of hepatopathy. (22) We recognize that the AUC of our model is suboptimal (0.753). However, only Hamaguchi et al. (26) assessed the accuracy of the measure in relation to the outcome (death) and the AUC were of 0.689 (males) and 0.693 (females), lower than our results. Perhaps a composite index would reach a better AUC, but the goal of our study was to compare preexisting tools and select the best for further evaluation, not to develop a new model. In our sarcopenic group, HCV infection was the worst prognostic factor (P 5 0.052). No other factor was significantly associated with survival, although male sex and HIV-positive infection tended to have a negative impact (P < 0.1). Sarcopenic HIV-positive patients (all of whom were HCV positive) had poor survival. To our knowledge, the negative impact of these 2 morbidities has not previously been reported in the literature. In the most recent series about HIV patients, sarcopenia was often described according to the European consensus (23) with muscle mass being calculated as appendicular skeletal muscle mass/height 2 . (43) (44) (45) This definition is not specific to HIV status, and the cutoffs were not calculated in this specific population. Until new studies for this subgroup of patients are published, we consider that the PMA measure may probably be also applied to HIV patients.
Given the high incidence of sarcopenia in patients with cirrhosis, and the retrospective single-center design of our study, we cannot contraindicate LT in sarcopenic patients. The aim of this study was simply to highlight the poorer prognosis in this population and to encourage clinicians to screen recipients for sarcopenia using an effective tool. In the future, sarcopenia as a recipient risk factor may be integrated in the algorithm for graft allocation and improve outcomes. Our findings now need to be confirmed in prospective series, and particular attention should be paid to both sarcopenic HIV-positive patients and those with HCV treated with new antiviral drugs, in order to confirm this major risk factor. Evaluation of sarcopenic status at listing (whereas a few months before LT) may also be an interesting prognostic value.
In conclusion, we compared the 4 most popular indexes defining sarcopenia in nonliver transplant patients and established cutoff values for PMA measured on a CT scan in patients with cirrhosis awaiting LT. These cutoff values for sarcopenia with respect to 1-year survival after LT were 1561 mm 2 in men and 1464 mm 2 in women. These measures could constitute a very useful tool for the estimation of nutritional status and the anticipation of post-LT risk. Our results suggest that the prognostic usefulness of PMA, although suboptimal, is superior to that of other adjusted measurements. The transplantation of sarcopenic male HIV-positive patients should be performed in very carefully selected cases because of their poor longterm survival. Our results now need to be tested on a prospective database in order to enable their definitive validation.
